Keros Therapeutics Inc (KROS) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $15.03
• Market Cap: $463.69M
• P/E Ratio: 9.76
• EPS: $1.56
• 52-Week High: $22.55
• 52-Week Low: $9.12

Market Sentiment

Keros Therapeutics Inc currently has a Neutral sentiment score of 0.13.

About Keros Therapeutics Inc

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts, dedicated to developing transformative therapies for hematological and musculoskeletal disorders. The company is advancing a proprietary pipeline of drug candidates designed to address significant unmet medical needs in these challenging therapeutic areas. With a strong focus on scientific innovation and comprehensive clinical development, Keros Therapeutics is strategically poise...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Keros Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does KROS pay dividends?

Keros Therapeutics Inc (KROS) does not currently pay a regular dividend.

What is KROS's P/E ratio?

Keros Therapeutics Inc has a price-to-earnings (P/E) ratio of 9.76.

What is KROS's market cap?

Keros Therapeutics Inc (KROS) has a market capitalization of $463.69M with a current stock price of $15.03.